Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs
Source : https://www.sciencedirect.com/science/article/abs/pii/S2213177923001853?via=ihub
Available online 17 May 2023 Author links open overlay panel, b c , , , , a e , , , , , g h , , , , l...
Conclusions: Utilization rates of SGLT2 inhibitors are low in patients with ASCVD, HF, and T2DM, with high residual facility-level variation. These findings suggest opportunities to optimize SGLT2 inhibitor use to prevent future adverse cardiovascular events.
Share
Shockwave lithotripsy of calcific stenosis of the distal abdominal aorta to facilitate transcatheter aortic valve replacement
Source : https://www.sciencedirect.com/science/article/abs/pii/S1553838923001616?via=ihub
The transfemoral approach for transcatheter aortic valve replacement (TAVR) is superior to alternative access strategies. Only transfemoral access has...
Relevance: We applied intravascular lithotripsy (IVL) to the distal abdominal aorta to achieve necessary luminal gain facilitating bioprosthetic aortic valve deployment.
Share
Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial - Trials
Source : https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07332-x
Background Heart failure with reduced ejection fraction (HFrEF) is associated with sleep dyspnea (SDB), which plays an adverse role in the pathophysiology of the condition. SDB management in HFrEF, however,...
Conclusion: In summary, our RCT will provide data for analyses of the relationship between OSA and dapagliflozin, which may be a potential treatment for sleep apnea.
Share
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Source : https://www.sciencedirect.com/science/article/pii/S0735109723050805?via=ihub
Empagliflozin reduces the risk of major heart failure outcomes in heart failure with reduced or preserved ejection fraction. The goal of this study was to evaluate the effect of empagliflozin...
Conclusions: The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.
Share
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy - Diabetology & Metabolic Syndrome
Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01061-6
Background Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This...
Conclusions: Empagliflozin may attenuate diabetic cardiomyopathy-related myocardial injury by promoting the catabolism of BCAA and inhibiting mTOR/p-ULK1 to enhance autophagy. These findings suggest that empagliflozin could be a potential candidate drug against BCAA increase and could be used for other cardiovascular diseases with a metabolic...
Share